Titre : Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
link : Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma RiskTreatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.
Continue reading: https://www.managedhealthcareconnect.com/content/direct-antiviral-therapy-hep-c-may-not-boost-hepatocellular-carcinoma-risk
Study: Gastroenterology 2018
On This Blog
HCC during and after direct-acting antiviral therapy in patients with hepatitis C
Index of research articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.
Thus articles Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
that is all articles Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk the link address https://newsaninpiration.blogspot.com/2018/08/direct-antiviral-therapy-of-hep-c-may.html
0 Response to "Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk"
Post a Comment